Drug ID:Drug138
Drug Name:GB004
CID:52912218
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT03860896, , NCT04556383
Molecular Formula:C22H28ClN3O4
Molecular Weight:433.9 g/mol
Isomeric SMILES:CC(C)(C)OC(=O)N1CCN(CC1)CC2=C(C(=O)N(C=C2)CC3=CC=C(C=C3)Cl)O
Synonyms:Izilendustat; 1303512-02-8; tert-butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate; Izilendustat [INN]; 2KL3NSB2NP; tert-butyl 4-[[1-[(4-chlorophenyl)methyl]-3-hydroxy-2-oxopyridin-4-yl]methyl]piperazine-1-carboxylate; 1-Piperazinecarboxylic acid, 4-((1-((4-chlorophenyl)methyl)-1,2-dihydro-3-hydroxy-2-oxo-4-pyridinyl)methyl)-, 1,1-dimethylethyl ester; MFCD32876908; UNII-2KL3NSB2NP; SCHEMBL1770480
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1102 52912218 Izilendustat 54583 EGLN1 Homo sapiens (human) Inhibitor

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03860896 GB004 in Adult Subjects With Active Ulcerative Colitis PHASE1 COMPLETED GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. Ulcerative Colitis DRUG: GB004|DRUG: Placebo|DRUG: GB004 Details
NCT04556383 A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC) PHASE2 TERMINATED GB004, Inc. Ulcerative Colitis DRUG: GB004|DRUG: Placebo Details
NCT04624230 Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis PHASE3 RECRUITING Pfizer Ulcerative Colitis DRUG: tofacitinib Details
NCT06651281 Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) PHASE3 RECRUITING Merck Sharp & Dohme LLC Crohn Disease|Colitis, Ulcerative DRUG: Tulisokibart|DRUG: Placebo to tulisokibart Details
NCT04857112 Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Bausch Health Americas, Inc. Ulcerative Colitis DRUG: Low Dose MT-1303|DRUG: High Dose MT-1303|DR… Details
NCT05986136 Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease PHASE2|PHASE3 RECRUITING Mostafa Bahaa Inflammatory Bowel Diseases DRUG: Mesalamine|DRUG: Dapagliflozin 10mg Tab Details
NCT06353828 Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients PHASE2 ACTIVE_NOT_RECRUITING CannaMore Biotechs Ulcerative Colitis DRUG: CBD, synthetic form|DRUG: Placebo Details
NCT04478825 Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis PHASE1 TERMINATED Bridge Biotherapeutics, Inc. Ulcerative Colitis DRUG: BBT-401-1S Details
NCT06570772 Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio PHASE3 RECRUITING Alvotech Swiss AG Ulcerative Colitis BIOLOGICAL: AVT16|BIOLOGICAL: Vedolizumab Details
NCT01290042 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. PHASE1 COMPLETED Amgen Ulcerative Colitis|Crohn's Disease DRUG: AMG 181|OTHER: Placebo for AMG 181 Details
NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 PHASE3 RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT00207688 A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients None COMPLETED Janssen Research & Development, LLC Ulcerative Colitis DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… Details
NCT04677179 A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) PHASE2 TERMINATED Nektar Therapeutics Colitis, Ulcerative DRUG: LY3471851|DRUG: Placebo Details
NCT02611830 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis PHASE3 COMPLETED Takeda Colitis, Ulcerative DRUG: Vedolizumab 300 mg IV|DRUG: Placebo IV|DRUG… Details
NCT02958865 Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis PHASE2 COMPLETED Pfizer Ulcerative Colitis DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… Details
NCT06420492 Study of Novel Therapeutics for Acute Remedy of Colitis PHASE2 NOT_YET_RECRUITING Brigham and Women's Hospital Ulcerative Colitis|Ulcerative Colitis Chronic Mod… DRUG: BRS201 Details
NCT03943550 Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) PHASE1 TERMINATED Hoffmann-La Roche Ulcerative Colitis DRUG: RO7049665|DRUG: Placebo Details
NCT04133194 Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis PHASE4 RECRUITING Flemming Bendtsen Ulcerative Colitis DRUG: Mesalazine|DRUG: Mesalazine Details
NCT02392221 Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2011). None COMPLETED Centre Hospitalier Universitaire, Amiens Pediatric Inflammatory Bowel Disease None Details
NCT05907330 Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis PHASE2 NOT_YET_RECRUITING Curacle Co., Ltd. Ulcerative Colitis DRUG: CU104|DRUG: Placebo Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S04 T-cell homing and retention T-cell trafficking vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab Inhibition of the interaction between α4β7 integrins on T c… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations